Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevabertinib vs Standard of Care in Advanced NSCLC with HER2 Mutations
NCT06452277Phase 3Recruiting
- Sponsor
- Bayer
- Start
- Aug 2024
- Primary completion
- Oct 2027
- Countries
- 36
01
Overview
A Phase 3 trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Started Aug 2024; status: recruiting.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06452277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452277.